Canaccord Genuity analyst John Newman maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $38 to $43.
Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.